EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSSTUG00000010196
Gene Symbol: LOC115149487
3 Cross references
81 Possible Orthologues:

Mitogen-Activated Protein Kinase 10-Like

Ensembl ID : ENSSTUG00000034312
Gene Symbol: LOC115159070
3 Cross references
82 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSSTUG00000044058
Gene Symbol: LOC115180302
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSSTUG00000017452
Gene Symbol: LOC115198903
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSSTUG00000021878
Gene Symbol: MAPK14
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSSTUG00000046979
Gene Symbol: MAPK14
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSSTUG00000009991
Gene Symbol: LOC115207356
3 Cross references
218 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSSTUG00000029968
Gene Symbol: LOC115151057
3 Cross references
217 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSSTUG00000026800
Gene Symbol: LOC115157756
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSSTUG00000035357
Gene Symbol: LOC115194041
3 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSSTUG00000011611
Gene Symbol: LOC115201108
3 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSSTUG00000006023
Gene Symbol: LOC115152965
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).